Sarepta Therapeutics Inc (SRPT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.72B
Last updated: Nov 17, 2026 at 11:06 AM ET
Sarepta Therapeutics Inc (SRPT) Earnings: Report Dates and Results
Sarepta Therapeutics (SRPT) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Sarepta Therapeutics reported EPS of -$0.10, below the $0.17 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SRPT has an expected report date of Feb 23, 2027.
SRPT Earnings Call
The latest SRPT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, SRPT beat 18 and missed 21. Revenue for the quarter ended Sep 30, 2026 was $381.35M, down 4.5% from $399.36M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.10 | $0.17 | -$0.06 - $1.06 | -158.82% | Miss | N/A | 10 | 0 up, 1 down | Nov 5, 2026 | $381.35M |
| Jun 30, 2026 | $0.42 | $0.34 | $0.11 - $0.79 | +23.53% | Beat | -79.2% | 9 | 1 up, 0 down | Aug 5, 2026 | $401.25M |
| Mar 31, 2026 | $3.16 | $1.05 | -$0.39 - $2.58 | +200.95% | Beat | N/A | 10 | 5 up, 2 down | May 6, 2026 | $730.80M |
| Dec 31, 2025 | -$3.58 | -$1.05 | -$1.88 - $0.37 | -240.95% | Miss | -288.4% | 11 | 5 up, 2 down | Feb 25, 2026 | $442.93M |
| Sep 30, 2025 | -$0.13 | -$0.37 | -$1.57 - $0.56 | +64.86% | Beat | -121.0% | 12 | 0 up, 5 down | Nov 3, 2025 | $399.36M |
| Jun 30, 2025 | $2.02 | $1.16 | $0.81 - $1.96 | +74.14% | Beat | +359.1% | 13 | 7 up, 5 down | Aug 6, 2025 | $611.09M |
| Mar 31, 2025 | -$3.42 | -$0.65 | -$3.95 - $3.14 | -426.15% | Miss | -568.5% | 12 | 1 up, 4 down | May 6, 2025 | $744.86M |
| Dec 31, 2024 | $1.90 | $2.06 | $1.32 - $2.64 | -7.78% | Miss | +304.3% | 11 | 5 up, 0 down | Feb 26, 2025 | $658.41M |
| Sep 30, 2024 | $0.62 | $0.37 | -$0.81 - $0.68 | +67.57% | Beat | +67.6% | 14 | 1 up, 1 down | Nov 6, 2024 | $467.17M |
| Jun 30, 2024 | $0.44 | $0.47 | N/A | -6.38% | Miss | N/A | 13 | 1 up, 0 down | Aug 7, 2024 | $362.93M |
| Mar 31, 2024 | $0.73 | $0.41 | N/A | +78.05% | Beat | N/A | 13 | 1 up, 0 down | May 1, 2024 | $413.46M |
| Dec 31, 2023 | $0.47 | $0.01 | -$1.03 - $0.61 | N/A | N/A | N/A | 17 | 2 up, 3 down | Feb 28, 2024 | $396.78M |
| Sep 30, 2023 | $0.37 | -$0.49 | -$1.95 - -$0.41 | +175.51% | Beat | N/A | 11 | 4 up, 0 down | Nov 1, 2023 | $331.82M |
| Jun 30, 2023 | -$0.85 | -$1.00 | N/A | +15.00% | Beat | N/A | 13 | 1 up, 1 down | Aug 2, 2023 | $261.24M |
| Mar 31, 2023 | -$0.97 | -$0.83 | -$1.61 - -$0.82 | -16.87% | Miss | N/A | 13 | 2 up, 0 down | May 2, 2023 | $253.50M |
| Dec 31, 2022 | -$1.24 | -$1.35 | -$1.85 - -$0.92 | +8.15% | Beat | N/A | 13 | 2 up, 0 down | Feb 28, 2023 | $258.43M |
| Sep 30, 2022 | -$0.80 | -$0.74 | N/A | -8.11% | Miss | N/A | 13 | 3 up, 0 down | Nov 2, 2022 | $230.27M |
| Jun 30, 2022 | -$1.18 | -$0.60 | N/A | -96.67% | Miss | N/A | 12 | 0 up, 1 down | Aug 2, 2022 | $233.49M |
| Mar 31, 2022 | -$0.56 | -$1.03 | -$1.72 - -$0.58 | +45.63% | Beat | N/A | 14 | 1 up, 0 down | May 4, 2022 | $210.83M |
| Dec 31, 2021 | -$1.42 | -$1.13 | -$1.99 - -$0.28 | -25.66% | Miss | N/A | 14 | 1 up, 0 down | Mar 1, 2022 | $201.46M |
| Sep 30, 2021 | -$0.19 | -$1.52 | -$2.34 - -$1.32 | +87.50% | Beat | N/A | 14 | N/A | Nov 3, 2021 | $189.41M |
| Jun 30, 2021 | -$1.52 | -$1.29 | -$2.06 - -$0.19 | -17.83% | Miss | N/A | 13 | N/A | Aug 4, 2021 | $164.09M |
| Mar 31, 2021 | -$1.54 | -$1.57 | -$2.50 - -$0.35 | +1.91% | Beat | N/A | 14 | N/A | May 5, 2021 | $146.93M |
| Dec 31, 2020 | -$2.40 | -$1.78 | -$2.18 - -$0.31 | -34.83% | Miss | N/A | 16 | N/A | Mar 1, 2021 | $145.14M |
| Sep 30, 2020 | -$1.42 | -$1.40 | -$2.45 - -$0.89 | -1.43% | Miss | N/A | 20 | N/A | Nov 5, 2020 | $143.92M |
| Jun 30, 2020 | -$1.51 | -$1.31 | -$3.24 - -$1.06 | -15.27% | Miss | N/A | 18 | N/A | Aug 5, 2020 | $137.36M |
| Mar 31, 2020 | -$0.23 | -$1.88 | -$3.11 - -$0.78 | +87.77% | Beat | N/A | 16 | N/A | May 6, 2020 | $113.67M |
| Dec 31, 2019 | -$1.57 | -$1.27 | N/A | -23.62% | Miss | N/A | 18 | N/A | Feb 26, 2020 | $100.11M |
| Sep 30, 2019 | -$1.14 | -$0.92 | N/A | -23.91% | Miss | N/A | 19 | N/A | Nov 7, 2019 | $99.04M |
| Jun 30, 2019 | -$0.83 | -$0.77 | N/A | -7.79% | Miss | N/A | 18 | N/A | Aug 7, 2019 | $94.67M |
| Mar 31, 2019 | -$0.75 | -$0.81 | -$3.63 - -$0.65 | +7.41% | Beat | N/A | 19 | N/A | May 8, 2019 | $87.01M |
| Dec 31, 2018 | -$2.05 | -$1.02 | -$1.44 - -$0.57 | -100.98% | Miss | N/A | 17 | N/A | Feb 27, 2019 | $84.42M |
| Sep 30, 2018 | -$0.56 | -$0.49 | -$1.70 - -$0.34 | -14.29% | Miss | N/A | 19 | N/A | Oct 24, 2018 | $78.49M |
| Jun 30, 2018 | -$0.43 | -$0.33 | N/A | -30.30% | Miss | N/A | 15 | N/A | Aug 8, 2018 | $73.53M |
| Mar 31, 2018 | -$0.28 | -$0.24 | N/A | -16.67% | Miss | N/A | 15 | N/A | May 3, 2018 | $64.60M |
| Dec 31, 2017 | -$0.37 | -$0.32 | -$0.56 - -$0.17 | -15.63% | Miss | N/A | 16 | N/A | Mar 1, 2018 | $57.28M |
| Sep 30, 2017 | -$0.33 | -$0.77 | N/A | +57.14% | Beat | N/A | N/A | N/A | Oct 25, 2017 | $45.95M |
| Jun 30, 2017 | -$0.65 | -$0.78 | N/A | +16.67% | Beat | N/A | N/A | N/A | Jul 19, 2017 | $35.01M |
| Mar 31, 2017 | -$0.60 | -$0.94 | N/A | +36.17% | Beat | N/A | N/A | N/A | Apr 27, 2017 | $16.34M |
| Dec 31, 2016 | -$0.87 | -$1.33 | N/A | +34.59% | Beat | N/A | N/A | N/A | Feb 28, 2017 | $5.42M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$5.11, after $3.69 the year before. It was -$4.16 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$5.11 | -238.5% |
| Dec 31, 2024 | $3.69 | N/A |
| Dec 31, 2023 | -$0.98 | N/A |
| Dec 31, 2022 | -$3.78 | N/A |
| Dec 31, 2021 | -$4.67 | N/A |
| Dec 31, 2020 | -$5.56 | N/A |
| Dec 31, 2019 | -$4.29 | N/A |
| Dec 31, 2018 | -$3.32 | N/A |
| Dec 31, 2017 | -$1.95 | N/A |
| Dec 31, 2016 | -$4.16 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 10,000 words across 22 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 10,305 | 22 | |
| 2026Q2 | Jun 30, 2026 | 9,477 | 26 | |
| 2026Q1 | Mar 31, 2026 | 7,357 | 17 | |
| 2025Q4 | Dec 31, 2025 | 12,340 | 25 | |
| 2025Q3 | Sep 30, 2025 | 9,568 | 25 | |
| 2025Q2 | Jun 30, 2025 | 8,729 | 16 | |
| 2025Q1 | Mar 31, 2025 | 10,265 | 23 | |
| 2024Q4 | Dec 31, 2024 | 12,401 | 26 |
2026Q3 Earnings Call
Opening remarks
Tam Thornton Senior Director of Investor Relations Thank you, Michelle, and thank you all for joining today's call. Earlier this afternoon, we released our financial results for the third quarter of 2026. The press release, along with our presentation slides and supplementary information, are available on the investor section of our company website. We plan to file our Form 10-Q for the quarter today with the SEC. Joining me on the call today are Mike Severino, our Chief Executive Officer, Dr. Louise Rodino-Klapac, President of Research and Development and Technical Operations, Patrick Moss, our Chief Commercial Officer, and Ryan Wong, our Chief Financial Officer. Additionally, joining us in the Q&A portion of the call are Ian Estepan, President and Chief Operations Officer, and Dr. James Richardson, our Chief Medical Officer. Before we begin the formal remarks, I would like to note that during this call, we will be making a number of forward-looking statements. Please refer to slide two of our presentation to view the formal text of these safe harbor statements. These statements involve varying risks and uncertainties, many of which are beyond Sarepta's control. Actual results could materially differ from these forward-looking statements, and such risks can adversely affect our business, our results of operations, and the trading price for Sarepta's common stock. We strongly encourage all listeners to review the company's most recent SEC filings for a detailed description of these applicable risks. Sarepta explicitly states that it does not undertake any obligation to publicly update or revise its forward-looking statements or financial projections based on subsequent events. Furthermore, please note that we will discuss non-GAAP financial measures during today's webcast. Complete descriptions and reconciliations of our GAAP to non-GAAP financial measures are included in today's press release and the accompanying slide presentation available to investors on our website. With that, I will now turn the call over to our CEO, Mike Severino.
Mike Severino CEO Thanks, Tam. Good afternoon, everyone, and thank you for joining us. It has been a little over 90 days since I joined Sarepta, and I want to begin by sharing a few reflections from that time and how they are shaping my priorities for the company. What initially attracted me to Sarepta was a combination that I believe is unique in biotech at our scale: an established commercial business and leadership position in Duchenne, a promising pipeline with the potential to produce differentiated medicines, and the financial strength to invest in that pipeline from our own commercial cash flows. After my first 90 days, I believe those fundamental strengths are very much intact.
Frequently Asked Questions About SRPT
When is Sarepta Therapeutics's next earnings date?
Sarepta Therapeutics's next earnings report is expected for Feb 23, 2027.
Did SRPT beat earnings estimates last quarter?
No. Sarepta Therapeutics reported EPS of -$0.10 for the quarter ended Sep 30, 2026, below the $0.17 estimate by 158.82%.
What EPS do analysts expect from SRPT next quarter?
The consensus EPS estimate for Sarepta Therapeutics for the quarter ending Dec 31, 2026 is -$0.37 from 24 analysts, with estimates from -$1.53 to $0.21.
How often does SRPT beat earnings estimates?
Sarepta Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -58.78%.
SRPT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors